Biocept Appoints Michael Nall as CEO
Biocept, Inc. announced today that it has appointed Michael W. Nall as President and Chief Executive Officer.
Mr. Nall’s extensive commercialization, sales and marketing experience will be a significant asset as the company brings its pipeline of OncoCEETM cancer diagnostic tests to the market. Mr. Nall has more than 25 years of leadership experience in healthcare sales, marketing, operations and reimbursement. He was most recently General Manager, North American Sales and Marketing at Clarient, a GE Healthcare Company. Previously, he served as Vice President of Sales and Reimbursement at Clarient during the time when that company was doubling the size of its sales team and rapidly growing revenues, and as Integration Leader during its successful acquisition by General Electric. A graduate of Central Missouri State University, Nall previously served as Account Executive at Impath, a cancer diagnostics company where he helped to commercialize the company’s cancer related testing.
“I am excited to join the Biocept team which is advancing diagnostics to improve cancer treatment. There is a clear advantage in molecular diagnostic solutions using standard blood samples and Biocept is poised to become a leader in this market. I look forward to helping drive sales of Biocept’s currently available OncoCEE-BRTM test for breast cancer and to introduce and commercialize Biocept’s planned tests for other cancers including lung, colorectal, prostate melanoma and other solid tumors using Biocept’s technology platforms. The company’s proprietary technology platforms for the analysis of circulating tumor cells and circulating tumor DNA are designed to address the molecular status of tumors utilizing blood samples.” said Nall.
David F. Hale, Executive Chairman of Biocept, commented, “Mike brings to Biocept a significant background of experience in the diagnostic industry and especially in the field of cancer diagnostics. He has been involved with and understands all aspects of the commercialization process for cancer diagnostics. His experience in helping Clarient grow from a start-up to over $100 million in revenue and acquisition by GE will serve Biocept well.”
Contact:
The Ruth Group
Melanie Sollid
646-536-7023